他克莫司(Tacrolimus) - 药物靶点：CaN_在研适应症：春季角膜结膜炎，间质性肺疾病，小肠移植排斥_专利_临床

概要

基本信息

药物类型

分子胶

别名

Inhaled tacrolimus、mdc-GRT、Nano-Tacrolimus

+ [61]

靶点

CaN

作用方式

抑制剂

作用机制

CaN抑制剂(钙神经素抑制剂)

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [11]

在研适应症

春季角膜结膜炎间质性肺疾病小肠移植排斥+ [81]

非在研适应症

急性胸部综合征急性移植物抗宿主病伴有 11q23 异常的急性髓系白血病+ [123]

原研机构

Astellas Pharma, Inc.

在研机构

City of Hope National Medical Center

Fred Hutchinson Cancer Research Center

CHIESI Farmaceutici SpA

+ [26]

非在研机构

Novartis Pharmaceuticals Corp.

Mc2 Therapeutics AS

Barbara Ann Karmanos Cancer Institute

+ [20]

权益机构

Aequus Pharmaceuticals, Inc.

Veloxis Pharmaceuticals A/S

Taiba Pharma

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (1994-04-08),

器官移植排斥

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本)、孤儿药 (韩国)

登录后查看时间轴

结构/序列

分子式C44H71NO13

InChIKeyNWJQLQGQZSIBAF-MLAUYUEBSA-N

CAS号109581-93-3

关联

1,459

项与他克莫司相关的临床试验

NCT07493538

/ Not yet recruiting临床2期IIT

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis.

开始日期2026-08-01

申办/合作机构

University of Minnesota Masonic Cancer Center

NCT06084780

/ Not yet recruiting临床2期IIT

Prospective Case Series of Intestinal and Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)

The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments. Participants will undergo intestinal/multivisceral transplantation. Participants will be followed for 12 months to assess efficacy and safety.

开始日期2026-08-01

申办/合作机构

The Case Comprehensive Cancer Center

NCT07519174

/ Not yet recruitingN/AIIT

A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With Mild to Moderate Atopic Dermatitis Over 8 Weeks

This randomized controlled trial compares the effectiveness and safety of topical tacrolimus 0.03% and crisaborole 2% in patients with mild to moderate atopic dermatitis over 8 weeks. Atopic dermatitis is a chronic inflammatory skin condition affecting quality of life, and steroid-sparing treatments are increasingly preferred due to adverse effects of long-term corticosteroid use. Tacrolimus, a calcineurin inhibitor, and crisaborole, a PDE-4 inhibitor, are both effective alternatives, though tacrolimus may offer greater efficacy while crisaborole has better tolerability. The study will include 70 patients aged 2-20 years, randomized into two groups receiving either treatment. Outcomes will be assessed using EASI score reduction and adverse effects. Data will be analyzed statistically to determine significance. The study aims to generate local evidence to guide treatment decisions and improve management strategies for atopic dermatitis in the Pakistani population.

开始日期2026-06-01

申办/合作机构

Foundation University Islamabad

100 项与他克莫司相关的临床结果

登录后查看更多信息

100 项与他克莫司相关的转化医学

登录后查看更多信息

100 项与他克莫司相关的专利（医药）

登录后查看更多信息

23,747

项与他克莫司相关的文献（医药）

2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Maintenance management after dupilumab discontinuation in moderate-to-severe atopic dermatitis: a comparative study of proactive intermittent tacrolimus and reactive rescue therapy

Article

作者: Li, Zaibing ; Tang, Yan

BACKGROUND:

Moderate-to-severe atopic dermatitis (AD) often relapses after dupilumab discontinuation. This study compared proactive intermittent tacrolimus versus on-demand therapy for post-discontinuation maintenance.

METHODS:

This was a real-world, mixed retrospective-prospective observational study conducted at a single dermatology center. Patients who discontinued dupilumab were identified through retrospective chart review, and a subset was followed prospectively. Based on observed post-discontinuation topical management patterns, patients were classified into a proactive maintenance group or a reactive, as-needed treatment group. Patients were followed for 24 weeks, with extended follow-up to 52 weeks for exploratory analyses. The primary outcome was time to first flare.

RESULTS:

Median follow-up was 28 weeks. Proactive maintenance prolonged flare-free survival (HR 0.62, 95% CI 0.45-0.86, p = 0.004), reduced flare rate (IRR 0.68, 95% CI 0.52-0.88, p = 0.003), and lowered steroid use (mean difference -18.4 g, p < 0.001). PROs improved more (POEM β -2.1; DLQI β -1.8). Local reactions were comparable (8.3 vs. 7.9%); no serious adverse events occurred.

CONCLUSION:

Proactive intermittent tacrolimus after dupilumab reduces flare risk and steroid burden, improving outcomes, and is a feasible maintenance strategy.

2026-04-01·JOURNAL OF ETHNOPHARMACOLOGY

Integrated metabolomics and proteomics analysis elucidated the therapeutic effect of Huangkui Capsule on tacrolimus-induced chronic nephrotoxicity in rats

Article

作者: Tang, Tingting ; Zhang, Feng ; Han, Jun ; Tao, Xia ; Yang, Liyuan ; Pang, Tao ; Li, Jingjing ; He, Yuqiong ; Yang, Hong ; Chen, Wansheng ; Wang, Yejian

ETHNOPHARMACOLOGICAL RELEVANCE:

Huangkui capsule (HK) has demonstrated significant efficacy in managing chronic kidney disease. Previous studies have shown that HK can alleviate kidney damage; however, the therapeutic effects of HK on tacrolimus-induced chronic nephrotoxicity (TCN) and the underlying molecular mechanisms remain unclear.

AIM OF THE STUDY:

To evaluate the effectiveness of HK in alleviating TCN and to explore its underlying mechanisms of action.

MATERIALS AND METHODS:

The therapeutic efficacy of HK was evaluated on the TCN rat model using biochemical indices and histopathological examinations. Integrated kidney metabolomic and proteomic profiling were analyzed to reveal the TCN related distinct dysregulated pathways and potential targets, and provide mechanistic insights into the relationship between targets and active components from HK. Molecular docking and Western blot analyses were further used for the validation.

RESULTS:

TCN rats showed increased proteinuria and a deterioration of kidney function, accompanied by increased inflammation and oxidative stress, whereas HK improved kidney damage in a dose-dependent manner. Integrated metabolomics and proteomics analyses showed that HK inhibited TCN by the restoration of glutathione metabolism and upregulation of Gclc, Gclm, Slc7a11, Slc3a2, and Gpx4, and revealed a specific regulatory mechanism of ferroptosis by the constructed "protein-pathway-metabolite" network analysis. Mechanistically, tacrolimus intervention increased intracellular Fe²⁺ levels, suppressed system xCT activity by downregulation of Slc7a11 and Slc3a2, and reduced Gpx4 levels, thereby increasing susceptibility to ferroptosis. Tamarixetin and quercetin-7-O-β-glucuronide from HK could reverse these effects, restoring expression levels of Slc7a11, Slc3a2, and Gpx4, exhibiting effects comparable to Fer-1.

CONCLUSIONS:

HK attenuated TCN through suppression of ferroptosis, as demonstrated by integrated metabolomic and proteomic analyses. This protective effect was mediated by its bioactive components, specifically quercetin, tamarixetin, and quercetin-7-O-β-glucuronide, which enhanced GSH synthesis and inhibited lipid peroxidation via upregulation of Slc7a11/Slc3a2 system.

2026-04-01·Transplantation Reviews

Tirzepatide in solid organ transplant recipients: Early real-world signals of efficacy and safety—A narrative review

Review

作者: Mazur, Gabriel Rian ; Corrêa, Lucas Maciel de Almeida ; de Marco, Patrícia Silva ; Santiago, Clara Belo Gamon ; Dante, Letícia Esteves ; Ferrés, Paola Beatriz Souza

Post-transplant metabolic management remains challenging, as immunosuppression exacerbates diabetes and obesity, threatening graft outcomes. While incretin-based therapies have transformed metabolic care, data on tirzepatide-a dual GIP/GLP-1 receptor agonist-in solid organ transplantation (SOT) are scarce. This review synthesizes early real-world evidence on tirzepatide's efficacy and safety in this high-risk population. A structured search of major databases identified 10 eligible reports; however, quantitative synthesis was restricted to the 6 studies (n = 182 recipients) providing disaggregated tirzepatide data. In this specific subset, tirzepatide demonstrated robust metabolic efficacy, with HbA1c reductions of 0.6-1.4 percentage points and weight loss of 5.5-6.9 kg. Crucially, renal parameters remained stable, with one study noting a modest eGFR increase (+3 mL/min/1.73 m²) and another reporting significant proteinuria reduction. Tacrolimus trough levels showed minimal fluctuation (Δ -0.2 to +0.2 ng/mL), suggesting no clinically significant pharmacokinetic interaction. Adverse events were predominantly gastrointestinal and manageable, with no signals of acute rejection or graft dysfunction. Despite limitations inherent to retrospective data and small sample sizes, preliminary evidence suggests tirzepatide is a potent strategy for cardiometabolic optimization in SOT, offering significant benefits without compromising graft function. These promising signals warrant confirmation in prospective, multicenter trials to definitively establish safety and long-term outcomes.

1,651

项与他克莫司相关的新闻（医药）

2026-04-14

·医科研

官方快审通道！影响因子2.0，接受率23%，审稿快速，最快10天接收

International Journal of Rheumatic Diseases 创刊于1998年，是亚太风湿病学会联盟（APLAR）的官方期刊。期刊专注于风湿性疾病、结缔组织病、自身免疫性疾病及过敏相关疾病的临床与实验研究，重点关注病因机制、诊断方法、治疗策略与患者管理。期刊接受多种类型的稿件，包括原创研究、综述、病例报告、简短通讯、社论与评论等。期刊收稿范围（包括但不限于）风湿性疾病的临床与实验研究结缔组织疾病相关机制与治疗自身免疫性疾病的基础与转化研究过敏与免疫相关疾病的病理机制骨与关节疾病的发生发展研究风湿病诊断、管理与预后探索新型治疗策略与药物干预研究亚洲及太平洋地区风湿病学进展期刊基本信息中文名称：《亚太风湿病学会联盟国际风湿病学杂志》出版社：Wiley ISSN：1756-1841; EISSN：1756-185X 出版国家：英国出版周期：月刊期刊网址：https://onlinelibrary.wiley.com/journal/1756185x 投稿网址：https://submission.wiley.com/submission/dashboard?siteName=APL 版面费：混合OA期刊， i：订阅模式无需版面费 ii：若选择OA期刊，需支付版面费 $3700（约合人民币26,435元）数据来源：期刊官网影响因子和分区 24年影响因子：2.0（相比于23年 2.4 下降）数据来源：IF查与投 JCR分区：Q3（JIF排名：35/58 风湿病学）数据来源：JCR官网中科院分区：数据来源：2025年期刊分区表自引率：期刊自引率总体呈上升趋势，2023年最高涨至21.22%，2024年回落到15.43%。数据来源：JCR官网审稿周期与近期研究主题 1.审稿速度期刊接受率23%，整体审稿周期较快；初审约24天，投稿到接收只需要93天，接收后出版也不慢16天。结合实际已发表Article统计审稿周期基本一致。根据期刊官网2024年信息统计（中位数）：数据来源：期刊官网结合2025年最新已发表文章（部分）信息统计，投稿到接受平均约 104天，最快 10 天，最慢 203天。接受到出版平均周期是 12 天。审稿周期：163天出版周期：28天文献题目：Exploring the Targets of Gulao Yukang Pill in Rheumatoid Arthritis via the Hippo Signaling Pathway: An Integrated Network Pharmacology and Experimental Validation Study 审稿周期：56天出版周期：8天文献题目：Identification of Causal Effects of Mitochondrial Dysfunction on the Risk of Multiple Autoimmune Disorders: Multi-Omics Mendelian Randomization and Colocalization Analyses 审稿周期：157天出版周期：13天文献题目：A Potential CD8+ T-Cell-Related Biomarker IFIT3 for Rheumatoid Arthritis 审稿周期：93天出版周期：7天文献题目：The Value of Rheumatoid Arthritis Citrullinated Peptides (RACP) System in the Diagnosis of Rheumatoid Arthritis: A Retrospective Analysis of 2632 Patients 审稿周期：78天出版周期：17天文献题目：Ubiquitin Ligase MDM2 Regulates Chondrocyte Damage, Ferroptosis, and Oxidative Stress by Modulating the Ubiquitination Level of CDKN1A 审稿周期：204天出版周期：12天文献题目：Toward Identifying a Multivariate Correlation of Septic Arthritis With a Machine Learning Approach: Time to Reset the Current Australasian Guidelines? 审稿周期：95天出版周期：6天文献题目：2024 Update of Chinese Guidelines for Management of Hyperuricemia and Gout Part II: Recommendations for Patients With Common Comorbidities 审稿周期：90天出版周期：7天文献题目：Association Between Traditional Chinese Medicine Use and Sepsis Risk and Glucocorticoid Exposure in Patients With Systemic Lupus Erythematosus: A Retrospective Cohort Study 审稿周期：188天出版周期：7天文献题目：Effects of Traditional Chinese Medicine Rehabilitation Program on Knee Osteoarthritis in Aging Population: A Multicenter Randomized Controlled Trial 审稿周期：187天出版周期：7天文献题目：Cervical Facet Joint Ankylosis in Patients With Axial Spondyloarthritis Serves as a Surrogate Radiographic Indicator of Propensity for Bone Formation 审稿周期：10天出版周期：14天文献题目：Endophilin A2, a Potential Therapeutic Target for Lupus, Promotes Lupus Progression 审稿周期：60天出版周期：14天文献题目：Evaluation of Vertebrae in Patients With Ankylosing Spondylitis Using Hounsfield Unit Values 审稿周期：32天出版周期：7天文献题目：Comparison of Outcomes Between Protocolized Tacrolimus-Based and Non-Protocolized Ciclosporin-Based Triple-Combination Therapy in Interstitial Lung Disease With Anti-MDA5-Positive Dermatomyositis: A Single-Center Retrospective Cohort Study 审稿周期：70天出版周期：14天文献题目：Palmitoylation Dynamics in Systemic Lupus Erythematosus: Multi-Omics Insights and Potential Therapeutic Implications 审稿周期：76天出版周期：14天文献题目：Decoding PANoptosis in Gout: Signature Gene Identification and Immune Infiltration Profiling2.发文数据发文量：期刊发文量近两年稳定在400+，2024总计发表425篇，2025年截至目前已发表336篇，预计会有所上涨。国人占比：国人占比总体呈上升趋势。2024年国人占比34.35%，2025年截至目前为38.39%，预计会稍有上涨。数据来源：MedReading 数据来源：Web of Science 3.近期主题方向近期以类风湿关节炎、系统性红斑狼疮、痛风及高尿酸血症为核心研究主题，聚集在疾病发病机制、临床诊断方法、并发症管理及治疗策略方面展开深入探讨。也包含与这些主题相关的研究，包括炎症反应、免疫浸润、骨与关节损伤，以及多种自身免疫性疾病的病理机制。当前热点还包括强直性脊柱炎、骨关节炎、系统性硬化症及干燥综合征等疾病的临床特征与治疗选择，同时，生物制剂与小分子靶向药物（如托法替尼、阿达木单抗、托珠单抗、司库奇尤单抗）在不同疾病中的应用与疗效评估也是重点方向。技术方法方面，网络药理学、Mendelian随机化、多组学分析、机器学习与人工智能等交叉手段正逐渐被用于疾病机制解析与预测模型构建，推动精准医学发展。整体上，期刊关注范围兼具基础与临床研究，既重视传统疾病研究，又积极接纳新兴方法学与跨学科研究成果。数据来源：MedReading 期刊诚信风险 1.JCAR指数 2023年三月份科瑞唯安官方一次性毫无征兆地剔除35本涉及学术诚信问题的期刊，让我们认识到CAR指数（一种评价期刊学术诚信风险的指数，超过10%为高风险，有被踢风险，越高代表风险越大）的重要性。该期刊2024年CAR指数是0%，2025年实时CAR指数是0.26%，评级：低风险（CAR Index＜5%）。数据来源：JCAR Index网站 2.撤稿数据 2025年起，Clarivate将影响因子计算剔除撤稿引文，强化对学术不端的监管。这也促使研究者在选刊时，更加关注期刊的撤稿记录与诚信表现。据期刊诚信舆情系统监测，期刊迄今总计1次撤稿记录（近两年无新增），累计5次PubPeer曝光，有1篇文章被Figcheck检测到图像重复问题。数据来源：MedReading 投稿建议《International Journal of Rheumatic Diseases》亚太风湿病学会联盟官方期刊（JCR Q3，中科院4区），影响因子2.0（24年相比23年小幅下降）。投稿初审反馈约24天，投稿至接受平均约104天（最快10天，最慢203天），接受后出版迅速（约12天）。期刊为混合OA模式，若选择OA需支付约人民币26,435元。对国人较为友好（2025年国人发文占比38.39%，呈上升趋势）。期刊诚信风险较低（CAR指数0.26%，近两年无新增撤稿，仅1次撤稿历史记录）。近期收稿主题集中在类风湿关节炎、系统性红斑狼疮、痛风、高尿酸血症及相关并发症管理，同时关注强直性脊柱炎、骨关节炎、系统性硬化症、干燥综合征及免疫治疗药物的应用，适合风湿病学、免疫学、临床诊疗及多组学交叉研究方向的作者投稿。扫码添加小编微信进群往期精彩合集生信专辑 | SEER数据库专辑 |临床预测模型 | SCI期刊投稿 R语言小白专辑 | 临床研究与meta | 文献深度解读版权声明本文来源：每日解刊，版权属于原作者，仅用于学术分享

2026-04-14

·百度百家

治疗银屑病新方法近年来，银屑病...@姚春海的动态

治疗银屑病新方法近年来，银屑病治疗领域通过生物制剂、小分子药物和精准光疗等创新手段，实现了从控制症状到长期缓解的转变。目前一线治疗方案以靶向炎症因子的生物制剂为主，配合外用免疫调节剂和光疗，能有效减少皮肤损伤并降低复发风险。 1. 生物制剂：针对特定炎症通路的单克隆抗体，如阿达木单抗、依那西普等，通过阻断TNF-α等关键因子，快速清除皮损并维持稳定。临床数据显示，80%患者治疗12周后皮损面积减少超75%，且长期使用安全性良好。 2. 小分子药物：JAK抑制剂（如托法替尼）和IL-23抑制剂（如乌司奴单抗）口服给药，避免注射给药的不便。适用于中重度患者，尤其对关节型银屑病效果显著，且能减少传统免疫抑制剂的副作用。 3. 外用新剂型：卡泊三醇倍他米松复方制剂、钙调磷酸酶抑制剂（如他克莫司软膏）等，结合角质层修复技术，可在局部快速起效，同时降低系统不良反应风险。 4. 光疗技术升级：308nm准分子激光与窄谱UVB联合应用，精准照射皮损部位，缩短治疗周期至每周2-3次，适合面部、黏膜等敏感部位，对儿童患者安全性更高。 #银屑病治疗# #生物制剂# #光疗技术# #小分子药物# #免疫调节#

2026-04-14

·药研苑

罗氏申请奥妥珠单抗新增自身免疫性相关肾病适应症

药品营销避坑”试读：药品导入期管理视频课（试听）药品生命周期管理（案例）药品立项需要注意什么（案例） 2026年4月10日国家药品监督管理局药品审评中心（CDE）网站显示，罗氏奥妥珠单抗注射液新适应症申请已获得CDE受理，预计本次申请的适应症为原发性膜性肾病或狼疮肾炎。原发肾病综合征按病理类型，可以分为膜性肾病（MN）、局灶节段性肾小球硬化症（FSGS）和微小病变性肾病综合征（MCD），具体病因尚不明确。原发性膜性肾病属于慢性自身免疫性疾病，可见免疫复合物在肾小球基底膜（GBM）沉积并伴随有肾小球基底膜增厚，导致蛋白质渗入尿液，肾功能逐渐下降。奥妥珠单抗用于原发性膜性肾病多中心、随机、开放标签3期临床试验MAJESTY研究共纳入142名患者。入组患者在标准治疗的基础上按1:1比例随机接受奥妥珠单抗或他克莫司（Tacrolimus）。2026年2月16日，罗氏宣布在MAJESTY研究中，奥妥珠单抗组与他克莫司组相比，2年完全缓解率达到统计学意义和临床意义的显著改善（Roche., 2026）。狼疮肾炎是系统性红斑狼疮常见的并发症。奥妥珠单抗用于活动性狼疮肾炎多中心、随机、安慰剂对照签3期临床试EGENCY研究共纳入271名患者。入组患者按1:1比例在标准治疗的基础上随机接受奥妥珠单抗或安慰剂。研究结果显示，至在第76周奥妥珠单抗组和安慰剂组的完全缓解率分别为46.4%和33.1%（P = 0.02）（Richard A Furie., 2025）。奥妥珠单抗（Obinutuzumab，佳罗华Gazyva）是糖基化结构改造的抗CD20单克隆抗体。通过抗体依赖性细胞毒性耗竭表达CD20的B细胞。其采用糖基化结构改造技术，能够增强细胞毒性。奥妥珠单抗2021年在国内上市，已批准的适应症为：本品与化疗联合，用于初治的 II 期伴有巨大肿块、III 期或 IV 期滤泡性淋巴瘤成人患者，达到至少部分缓解的患者随后用奥妥珠单抗维持治疗。在肾病领域，奥妥珠单抗用于成人狼疮肾炎已获得FDA批准。推荐指数：★★ 推荐原因：MAJESTY研究和EGENCY研究证实了奥妥珠单抗在治疗自身免疫性肾脏疾病中具有积极的意义，也使奥妥珠单抗从肿瘤领域，顺利进入自身免疫性疾病领域。相关阅读：第二个CTLA-4单抗，阿斯利康曲麦利尤单抗获批转移性NSCLC 首仿，迪赛诺抗HIV药物拉米夫定多替拉韦片获批首仿，苏州盛达药业盐酸头孢卡品酯颗粒获批上市独家，海融度骨化醇注射液获批治疗继发性甲状旁腺功能亢进荣昌生物HER2 ADC维迪西妥单抗获批一线治疗晚期尿路上皮癌独家儿童抗过敏药物，四环科宝盐酸奥洛他定口服溶液获得映恩生物HER2 ADC帕康曲妥珠单抗申请国内新药上市高苯丙氨酸血症治疗药物塞匹蝶呤已在国内申请上市热点品种，东阳光伏诺拉生注射液抢先申请上市默沙东申请贝组替凡新增用于晚期嗜铬细胞瘤或副神经节瘤 1类新药，凌科药业申请第2代JAK抑制剂泽普昔替尼上市第二家，人福药业申请上市多动症药物盐酸右哌甲酯缓释胶囊云顶新耀公布PCSK9抑制剂莱达西贝普中国3期临床试验结果明慧医药外用JAK抑制剂伊托法替布软膏申请上市远力健药业第四代促胃动力药酒石酸西尼必利片首仿获批相关内容只作为药物研发的参信息。不构成任何与用药咨询有关的建议。如需发稿，您可通过在药研苑公众号下以发送信息的方式将官网或官方公众号的稿件链接和标题发送给我们。我们将择优确定是否发布。

100 项与他克莫司相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08556	他克莫司	L04AD02 D11AH01	DB00864

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
春季角膜结膜炎	韩国	Taejoon Pharm Co., Ltd.	2019-07-11
间质性肺疾病	日本	Astellas Pharma, Inc.	2013-06-14
小肠移植排斥	日本	Astellas Pharma, Inc.	2011-07-26
溃疡性结肠炎	日本	Astellas Pharma, Inc.	2009-07-07
粘膜炎	日本	Senju Pharmaceutical Co., Ltd.	2008-01-25
同种异体移植排斥反应	欧盟	Astellas Pharma Europe BV	2007-04-23
同种异体移植排斥反应	冰岛	Astellas Pharma Europe BV	2007-04-23
同种异体移植排斥反应	列支敦士登	Astellas Pharma Europe BV	2007-04-23
同种异体移植排斥反应	挪威	Astellas Pharma Europe BV	2007-04-23
肝移植排斥反应	欧盟	Astellas Pharma Europe BV	2007-04-23
肝移植排斥反应	冰岛	Astellas Pharma Europe BV	2007-04-23
肝移植排斥反应	列支敦士登	Astellas Pharma Europe BV	2007-04-23
肝移植排斥反应	挪威	Astellas Pharma Europe BV	2007-04-23
狼疮性肾炎	日本	Astellas Pharma, Inc.	2007-01-26
胰腺移植排斥反应	日本	Astellas Pharma, Inc.	2005-01-19
肺移植排斥反应	日本	Astellas Pharma, Inc.	2003-01-31
心脏移植排斥反应	日本	Astellas Pharma, Inc.	2001-06-20
重症肌无力	日本	Astellas Pharma, Inc.	2000-09-20
特应性皮炎	日本	Maruho Co., Ltd.	1999-06-16
骨髓移植排斥反应	日本	Astellas Pharma, Inc.	1999-04-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肾/胰腺移植排斥	临床3期	美国	Veloxis Pharmaceuticals A/S	2019-02-27
终末期肾脏病	临床3期	美国	Northwestern University	2017-09-05
震颤	临床3期	美国	Veloxis Pharmaceuticals A/S	2011-12-01
侵袭性 B 细胞非霍奇金淋巴瘤	临床3期	美国	Dana-Farber Cancer Institute, Inc.	2009-06-01
霍奇金淋巴瘤	临床3期	美国	Dana-Farber Cancer Institute, Inc.	2009-06-01
惰性B细胞非霍奇金淋巴瘤	临床3期	美国	Dana-Farber Cancer Institute, Inc.	2009-06-01
惰性非霍奇金淋巴瘤	临床3期	美国	Dana-Farber Cancer Institute, Inc.	2009-06-01
套细胞淋巴瘤	临床3期	美国	Dana-Farber Cancer Institute, Inc.	2009-06-01
非霍奇金淋巴瘤	临床3期	美国	Dana-Farber Cancer Institute, Inc.	2009-06-01
T细胞淋巴瘤	临床3期	美国	Dana-Farber Cancer Institute, Inc.	2009-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01384513 (CTgov)	临床2期	复发性成人III级淋巴肉芽肿 \| 难治性血细胞减少伴多系发育不良和环状铁粒幼细胞 \| 复发性边缘区淋巴瘤 ... 更多	40	Allogeneic hematopoietic stem cell transplantation+Fludarabine+Busulfan+Cyclophosphamide (CY)+Tacrolimus+mycophenolate mofetil	構糧鹹蓋鑰鏇願鹽願餘 = 顧蓋糧觸窪壓顧願憲夢餘鏇鑰夢襯網鬱壓鬱鑰 (願醖簾範鹹鬱蓋顧鑰窪, 構壓遞糧範簾憲網淵願 ~ 獵鏇願顧製顧顧構膚獵) 更多	-	2026-04-15
NCT01203722 (CTgov)	临床1/2期	急性髓性白血病 \| 慢性淋巴细胞白血病 \| 急性淋巴细胞白血病 ... 更多	87	Allogeneic Blood or Marrow Transplant+Fludarabine+Cytoxan+Sirolimus+mycophenolate mofetil (REGIMEN B)	壓築襯鏇鏇遞願糧衊窪 = 鏇夢憲繭網衊鏇餘構願蓋鏇齋積蓋構鹹積製製 (築網觸鏇艱範顧構夢鑰, 膚願襯膚鹹餘獵遞窪糧 ~ 淵糧艱壓鹹夢齋淵繭鑰) 更多	-	2026-02-18
NCT01203722 (CTgov)	临床1/2期	急性髓性白血病 \| 慢性淋巴细胞白血病 \| 急性淋巴细胞白血病 ... 更多	87	Allogeneic Blood or Marrow Transplant+Fludarabine+Cytoxan+Tacrolimus+mycophenolate mofetil (REGIMEN C)	壓築襯鏇鏇遞願糧衊窪 = 蓋壓廠積積鏇蓋蓋願壓蓋鏇齋積蓋構鹹積製製 (築網觸鏇艱範顧構夢鑰, 鹽鑰獵獵願膚鑰餘窪願 ~ 糧獵鬱窪顧繭鑰網觸襯) 更多	-	2026-02-18
Tandem Meetings ASTCT and CIBMTR2026	N/A	移植物抗宿主病	73	PTCY, Abatacept, Tacrolimus	願鹹鏇網願艱壓繭廠築(壓廠觸願窪餘顧廠鏇憲) = 構醖壓鬱製築襯觸築鹹鹽淵憲積壓夢壓淵壓鏇 (糧憲鏇艱壓觸鏇選網鑰, 50.5 ~ 73.9) 更多	积极	2026-02-04
Tandem Meetings ASTCT and CIBMTR2026	N/A	造血干细胞移植	22	Intermittent IV bolus tacrolimus	製齋鏇醖獵築齋齋鑰獵(選淵築鬱繭簾艱憲壓艱) = 廠獵築鹽醖鏇鑰膚蓋鹽遞廠蓋壓範鹽顧壓遞壓 (遞製蓋願繭觸積淵糧襯 ) 更多	积极	2026-02-04
NCT06348602 (Tandem Meetings ASTCT and CIBMTR2026)	临床1/2期	移植物抗宿主病	22	Topical Cyclosporine	顧淵遞衊積衊築簾願襯(鬱鏇醖繭窪蓋蓋網鹽糧) = Both treatments were well tolerated: burning 70% Cys vs 55% Tac; pruritus 15% vs 45%; blurred vision 30.7% vs 36.4%. No discontinuations occurred. 願獵糧襯膚積觸簾衊憲 (築醖積齋壓餘廠範膚簾 ) 更多	积极	2026-02-04
NCT06348602 (Tandem Meetings ASTCT and CIBMTR2026)	临床1/2期	移植物抗宿主病	22	Topical Tacrolimus		积极	2026-02-04
Tandem Meetings ASTCT and CIBMTR2026	N/A	移植物抗宿主病	121	Post-transplant cyclophosphamide with tacrolimus and mycophenolate (PTCy-Tac-MMF)	夢顧淵遞餘糧夢積膚遞(鬱繭獵夢齋構夢襯餘遞) = 築廠觸獵簾衊艱壓夢糧簾鑰憲網齋顧蓋襯鏇鹹 (鹽壓範築鹹構膚積糧壓, 10.5 ~ 38.1) 更多	相似	2026-02-04
Tandem Meetings ASTCT and CIBMTR2026	N/A	移植物抗宿主病	121	Tacrolimus+Methotrexate	夢顧淵遞餘糧夢積膚遞(鬱繭獵夢齋構夢襯餘遞) = 鹽網鬱糧遞顧獵簾顧選簾鑰憲網齋顧蓋襯鏇鹹 (鹽壓範築鹹構膚積糧壓, 4.1 ~ 17.3) 更多	相似	2026-02-04
Tandem Meetings ASTCT and CIBMTR2026	N/A	-	30	Post-transplant cyclophosphamide, Tacrolimus, Sirolimus	鑰鏇鏇鬱製顧壓選獵簾(獵選鏇憲鹹鑰襯夢廠築) = 膚獵顧獵憲簾膚築窪壓齋膚蓋繭廠衊壓鹽鏇願 (獵鬱鹽鑰壓醖蓋願選壓, 31.3 ~ 66.1) 更多	积极	2026-02-04
Tandem Meetings ASTCT and CIBMTR2026	N/A	急性髓性白血病	48	Fludarabine/Melphalan (Flu/Mel) Conditioning Regimen	淵願淵鏇選壓鑰範憲構(窪夢繭鹹窪廠壓膚窪築) = 選鏇夢膚獵蓋構網鏇膚衊簾餘簾醖衊積壓鏇窪 (淵網齋衊鹽憲積網艱淵, 62 ~ 87) 更多	积极	2026-02-04
NCT05115630 (CTgov)	临床2期	髓系肿瘤 \| 急性髓性白血病 \| 慢性期慢性髓性白血病 ... 更多	24	TBI+Fludarabine+Melphalan	繭淵淵蓋餘窪製範艱構 = 憲廠窪簾廠繭廠簾蓋鹽醖窪遞觸願蓋醖觸積遞 (鬱鏇繭鹽壓淵鏇觸鹹窪, 製網醖製觸積鹽鹹鏇積 ~ 獵範遞鏇遞廠窪簾構簾) 更多	-	2025-12-19
NCT03979365 (SIMPLE, CTgov)	临床4期	肾移植排斥反应	261	Tacrolimus twice daily (Tacrolimus Twice-daily)	範衊餘遞壓淵積蓋繭選(簾艱夢網網艱襯積衊夢) = 積齋淵餘鏇衊鹹鹽夢艱襯網餘積廠鏇齋餘積構 (顧鬱築壓鏇膚範壓夢構, 14.053) 更多	-	2025-12-18
NCT03979365 (SIMPLE, CTgov)	临床4期	肾移植排斥反应	261	Envarsus XR (Envarsus XR)	範衊餘遞壓淵積蓋繭選(簾艱夢網網艱襯積衊夢) = 範鏇醖選願襯鹽醖鑰襯襯網餘積廠鏇齋餘積構 (顧鬱築壓鏇膚範壓夢構, 14.846) 更多	-	2025-12-18